CME/CE

By ReachMD

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncolo... more

· Medicine

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about CME/CE:

How many episodes does CME/CE have?

The podcast currently has 1,107 episodes available.

CME/CE episodes:

March 31, 2025 Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Host: Fortunato Ciardiello, MD, PhD
Host: Jenny Seligmann, MBChB, PhD

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
...more
6min
March 31, 2025 Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Host: Fortunato Ciardiello, MD, PhD
Host: Jenny Seligmann, MBChB, PhD

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
...more
6min
March 31, 2025 Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Host: Fortunato Ciardiello, MD, PhD
Host: Jenny Seligmann, MBChB, PhD

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
...more
6min
March 31, 2025 Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
Host: Harry Yoon, MD
Guest: Jaffer Ajani, MD

This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.

Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

...more
7min
March 31, 2025 ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
Host: Harry Yoon, MD
Host: Jaffer Ajani, MD

This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.

Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

...more
5min
March 31, 2025 Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
Host: Harry Yoon, MD
Host: Jaffer Ajani, MD

This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.

Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

...more
5min
March 31, 2025 The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
Host: Harry Yoon, MD

This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.

Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

...more
6min
March 31, 2025 Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
Host: Harry Yoon, MD
Host: Jaffer Ajani, MD

This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.

Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

...more
5min
March 31, 2025 Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
Host: Jaffer Ajani, MD

This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.

Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

...more
6min
March 31, 2025 The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
Host: Harry Yoon, MD
Host: Jaffer Ajani, MD

This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.

Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

...more
5min

FAQs about CME/CE:

How many episodes does CME/CE have?

The podcast currently has 1,107 episodes available.